both B. melitensis and B. abortus in their culture and/or antibody test. There was no significant difference between the groups in terms of clinical cure, all-cause mortality, LOS, and end of therapy temperature, white blood cells counts, C-reactive protein levels, and erythrocyte sedimentation rates.

**Conclusion.** Due to lack of differences in clinical outcomes, all-cause mortality, LOS, and end of therapy parameters between the three groups, a regimen comprising two, rather than three, agents (namely doxycycline and rifampin) can be sufficient. Such finding complies with previous studies although replacing rifampin with an aminoglycoside might be superior per the World Health Organization guidelines for the treatment of brucellosis. Further studies with a larger sample size are warranted to confirm these findings.

**Disclosures.** All authors: No reported disclosures.

423. **Ten-Year Experience of Burkholderia pseudomallei Infections in a Singapore Tertiary Hospital**

Mark Mau Shin Phah,1 Justin Shiang Lin1, Monica Chan, BMBS, BMedSci, MRCP, MCPF,2 Yee-Sin Leo, MPH, FAMS, FRCP3 and Shawn Vassos, MBBS, MRCP, D(ABIM), D(ABP)4;1 Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore, 2Lee Kong Chian School of Medicine, Singapore, Singapore, 3Infectious Diseases, Institute of Infectious Diseases and Epidemiology, Tan Tock Seng Hospital, Singapore, Singapore, 4Department of Infectious Diseases, Institute of Infectious Diseases and Epidemiology, Tan Tock Seng Hospital, Singapore, Singapore

**Session:** 57. Global Health and Travel Medicine
Thursday, October 4, 2018: 12:30 PM

**Background.** Burkholderia pseudomallei is endemic in the tropics and associated with high mortality. We performed a retrospective study analyzing the clinical and microbiologic features of melioidosis, and predictors of mortality.

**Methods.** Patients with culture-positive melioidosis from 2006 to 2016 were identified from microbiologic records. Clinical data including demographics, treatment, and outcomes were extracted from medical records. Categorical variables were compared using χ² test or Mann–Whitney U test.

**Results.** Forty-three cases of melioidosis were identified. Presentations included fever (41.9%), respiratory symptoms (20.9%), and joint swelling (9.3%). 76.7% were polymicrobial with a median Pitt Bacteremia Score (PBS) (100.0%), trimethoprim–sulfamethoxazole (92.1%), amoxicillin–clavulanate (94.7%), and doxycycline (94.7%). Mean time from presentation to melioidoid-coverage was 6.8 ± 1.9 days. Thirty-day all-cause mortality occurred in nine patients (from first positive culture), one patient died within 5 months. Univariable analysis associations with mortality included: high median Pitt Bacteremia Score (p = 0.01), receipt of ceftazidime (vs. a carbapenem) as primary induction antibiotic therapy (OR 0.2, 95% CI 0.03–0.91, p = 0.047) and not receiving melioidosis-active induction intravenous antibiotics (P = 0.04). Multivariable analysis found mechanical ventilation to be an independent predictor for 30-day mortality (p = 0.003, OR 18.8, 95% CI 2.7–130.9).

**Conclusion.** ICU admission, a high PBS, and in particular, receipt of mechanical ventilation may help identify patients with high mortality risk. Delays in melioidose therapy were not uncommon. Prompt recognition of melioidosis and early institution of active therapy, especially in the critically ill, may reduce mortality.

**Disclosures.** All authors: No reported disclosures.

424. **Southern Arizona Town: Homes Colonized by Kissing Bugs? Is Chagas Disease Being Transmitted?**

Norman Beatty, MD,1 Nicole Bradley-Behrens, PhD2; Maria Love, BS3; Shannon Smith, MBA1; Nafees Ahmad, PhD3 and Stephen Klotz, MD4; 1Division of Infectious Diseases, Department of Medicine, University of Arizona College of Medicine, Tucson, Arizona, 2Department of Immunobiology, University of Arizona College of Medicine, Tucson, Arizona

**Session:** 57. Global Health and Travel Medicine
Thursday, October 4, 2018: 12:30 PM

**Background.** Bisbee, Arizona is a small mining community established 1880, located 11 miles from the United States–Mexico border with a total population of 70. When asked whether they had changed their sleeping patterns due to triatomine bites, 90.9% of respondents were able to identify at least one triatomine, 90.9% being able to identify T. recurva. Seventy percent of homes used either a swamp cooler or central air conditioning. Only one home had used pesticides in an attempt to exterminate insects. All homeowners reported various wildlife near their home, including javelina, pack rat, rock squirrel, mule deer, and raccoon (Figure 1). Homeowners were asked to correctly identify these triatomines in a photo line-up of similar insects, and 75% of participants made a successful identification of at least one triatomine, 90.9% being able to identify T. recurva. When asked whether they had changed their sleeping patterns due to triatomine bites, 45.5% (10/22) had done so. The same surveyed group rated their frustration with triatomines in their home on scale of 1–10 (10 being the most frustrated) revealing a mean rating of 8.6 with nine individuals reporting 10. CDPD rapid tests among participants (N = 22) were all negative for serological evidence of T. cruzi infection.

**Conclusion.** Despite exposure to T. cruzi-positive triatomines among these household residents, some having sustained hundreds of bites throughout the years, we do not have evidence of transmission of Chagas disease. These are preliminary findings and further study is underway.

**Figure 1.**

| Characteristic of home | Result |
|------------------------|--------|
| Median age of home     | 91 years |

**Table 1: Results of home evaluation of owners bitten by kissing bugs (N=17)**

| Persons / home | 2.2 people |
| Cats / home    | 1.0 dogs   |
| Use cooler or air conditioning | 70% |
| Use pesticides | 6% |

**Disclosures.** All authors: No reported disclosures.

425. **Chikungunya in Solid-Organ Transplant Recipients, a Case Series and Literature Review**

Fernando Rosso, MD1; Sarita Rodriguez, MD1; Jorge Cedano, MD2 and Barbara Lucia Mora, MD1; Infectious Diseases, Fundación Valle del Lili, Cali, Colombia, 2Clinical Research Center, Fundacion Valle del Lili, Cali, Colombia

**Session:** 57. Global Health and Travel Medicine
Thursday, October 4, 2018: 12:30 PM

**Background.** Chikungunya virus is a recent emerging arbovirus in Latin America. Clinical manifestations can vary from fever and rash to severe chronic inflammatory arthritis. Few reports have been published regarding this infection in immunocompromised patients, including in solid-organ transplant (SOT) recipients.

**Methods.** We presented a case series of SOT recipients with confirmed Chikungunya infection by positive RT-PCR (LightMix® kit Chikungunya-virus, Light Cycler® Roche Diagnostics), during the 2015 epidemic in Colombia. In addition, we conducted a literature review, searching PUBMED, EMBASE, LILACS regarding Chikungunya infection in SOT recipients.

**Results.** Ten SOT recipients were included (five kidney, four liver, and one liver/kidney transplant). The mean age of the transplant recipients was 47 years, 70% were women. The most frequent symptoms were arthralgia and fever. None of the patients required treatment in the intensive care unit; no fatal cases or graft rejection were reported. None of our patients had recurrent arthritis during the three months follow-up. In the literature review, we found 21 cases reported. All of them had a benign clinical course with no severe complications or death. No chronic inflammatory arthritis cases were reported.

**Conclusion.** CHIK infection in SOT recipient have a benign course, and have no chronic recurrent arthritis. We proposed that immune suppression could decrease the risk of severe or chronic inflammatory manifestations.

**Disclosures.** All authors: No reported disclosures.

426. **Post-chikungunya Chronic Disease and Its Impact on Quality of Life, Depression, Anxiety, Fatigue and Sleep Quality: Results From a 2-Year Follow-up Comparative Study of 62 Patients in La Virginia, Risaralda, Colombia**

Alonso [Rodriguez-Morales, MD, MSc, DTM&H, FSTHM&H(Lon)], FTTM FICSGAN(Col), FACC, Julio César Gutierrez-Segura, MD1;2; Sabina Ocampo-Serna, MD1;2; Oscar Mauricio Meneses-Quintero, MD1;2; Sergio Andrés Ochoa-Oroco, MD1;2; Diana Marcela Sánchez-Castaño, MD1;2; Karol Liceth Hoyos-Guapacha, BSc;1 Geraldine Botero-Castaño, BSc2;2; Jairo Daniel Corzo-Romero, BSc;2; José Yomima Erazo-Landázuri, BSc;2; Diana Fiorella López-Caceda, BSc;2; Julian David Montoya-Bernal, BSc;2; Tomas Franco-Duque, BSc2;2; Jairo Andrés Gonzalez-Ospina, BSc;2; Mario Marín-Peralta, BSc;2; Carlos Andrés Ramirez-Arango, BSc;2; Mario Suárez-Tabares, BSc2;2; Juan Daniel Castrillón-Spita, MD1;2; José J. Londoño, MD1;2; Héctor D. Bedoya-Rendón, BSc;2; Javier De Jesús Cádiz-Pérez, MSc;2; Jaime
Background. There are limited studies in Latin America regarding the chronic consequences of Chikungunya virus (CHIK) infection, known as post-CHIK chronic disease (pCHIK-CD), and its impact, not just on organic but also mental conditions. We assessed the longest follow-up cohort of pCHIK-CD in Latin America, at La Virginia municipality, Risaralda, a new endemic area of CHIK in Colombia.

Methods. We conducted a follow-up cohort ambispective study in Colombia of 62 patients diagnosed with CHIK that persisted with pCHIK-CD after >2 years (February 2015–December 2017), initially serologically confirmed. Cases were followed-up and assessed with the validated instruments: quality of life (QoL) 36-item short-form health survey (SF-36), Zung Self-Rating Depression Scale (SDS) Zung Self-Rating Anxiety Scale (SAS), Pittsburgh Sleep Quality Index (PSQI) (licensed), and Fatigue Severity Scale (FSS).

Results. We compared 43 patients with persistent disease (pCHIK-CD+) and 19 controls (pCHIK-CD-). Mean age 44.1 years old, 69% female. Differences in SF-36 median scores between both groups were pCHIK-CD: 83.2% and pCHIK-CD+: 51.4% (P < 0.0001), in six dimensions (physical functioning [89.5%/62.1%], role physical [89.5%/39.0%], bodily pain [88.2%/44.4%], general health [77.7%/51.4%], vitality [79.5%/59.6%] and health transition [68.4%/40.7%]), differences were significant (P < 0.05). Depression and anxiety symptoms were significantly higher among those with pCHIK-CD+: 48.8%/21.1% (P = 0.04) and 97.7%/84.2% (P = 0.047). Moderate-to-severe scores at SDS and SAS showed marked difference in those pCHIK-CD+ (P ≥ 0.039). At the PSQI we found significant differences at wake-up time for pCHIK-CD+ (early, P = 0.0069), sleep less time (P = 0.0121), and with more somnolence (P = 0.0066). FSS were significantly higher in those with pCHIK-CD+, 55.2:37.5 (P = 0.0213).

Conclusion. According to our results, after 2 years CHIK patients persisted with chronic disease, including impairment in QoL, depression, anxiety, sleep quality and fatigue. These results support previous case reports from La Reunion (France) and Colombia, but show new impacts on mental health in a long-term follow-up for a chronic disease, including impairment in QoL, depression, anxiety, sleep quality and fatigue. These results support previous case reports from La Reunion (France) and Colombia, but show new impacts on mental health in a long-term follow-up for a chronic disease. These findings have significant implications in areas affected by chikungunya epidemics, as well later endemic areas with chronic disease.

Disclosures. All authors: No reported disclosures.

This abstract has been withdrawn at the author’s request.